{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-007674","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.690082+00:00","generated_at":"2026-05-16T03:09:41.249443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artivion Q4 revenue $116M (+19%), GAAP net income $2.4M; full year $441M","bullets":["GAAP revenue Q4 $116.0M vs $97.3M, net income $2.4M ($0.05 diluted EPS) vs net loss $16.5M in Q4 2024.","Adjusted revenue (ex Italian reserve) $118.3M, up 18% constant currency; adjusted EBITDA $22.7M (+29%).","Full year 2025 GAAP revenue $441.3M vs $388.5M; GAAP net income $9.8M vs loss $13.4M.","Filed final PMA module for AMDS Hybrid Prosthesis with FDA; positive NEXUS TRIOMPHE clinical data at STS meeting.","Non-GAAP net income Q4 $8.6M ($0.17 per share); full year $29.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-007674","json":"https://secwatch.observer/filing/0001628280-26-007674.json","markdown":"https://secwatch.observer/filing/0001628280-26-007674.md","text":"https://secwatch.observer/filing/0001628280-26-007674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000162828026007674/0001628280-26-007674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000162828026007674/aort-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:09:41.249443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}